# Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine

> **NCT01625689** · PHASE2 · COMPLETED · sponsor: **PATH Vaccine Solutions** · enrollment: 309 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** SIIL LAIV (live, trivalent seasonal influenza vaccine)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01625689
- **Lead sponsor:** PATH Vaccine Solutions
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2015-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625689, "Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01625689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*